Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: There are many drugs for of symptomatic fibroids. Gonadotropin-releasing hormone (GnRH) agonists are the well known drugs. Also, aromatase inhibitors are effective. All published studies surveyed the effect of one of these two drugs. In this study as the first study decided to evaluate the effectiveness of the combination of GnRH agonists + aromatise inhibitor on the uterine fibroids. Methods: A cross-sectional prospective case series study was performed on 10 known cases of uterine fibroids late perimenopause, at least 3 myomas >5 cm, abnormal uterine bleeding and anemia due to fibroids, candidate for hysterectomy, no tendency to surgery. A single dose of Diphereline 11.25 mg, SR plus 2.5 mg of Letrozole daily for 4 weeks with add-back therapy + calcium carbonate were used. The second dose of Diphereline 11.25 mg, SR was used 3 months after the first injection. The patients were followed until 3 years. Results: The mean age of the study group was 49.90 ± 1.66. The mean fibroid size reduced from 15.05 ± 57.20 cm to 13.56 ± 39.39 cm (P = 0.012) and fibroid volume reduced from 72.78 ± 110.6 to 50.96 ± 64.2 (P = 0.116). There was no signification changes in the serum level of hormones at the end of six months. Eight cases were menopause at the end of the study and hypoestrogenism symptoms did not happened in none of the cases until the end of 24 months. Except in one case, there was no need to do surgery on others. Conclusions: Combination of Diphereline + Letrozole probably could prevent surgery in cases that have multiple fibroids, perimenopause, anemic and candidate for surgery. (J Menopausal Med 2018;24:62-66)
Abstract
Objectives: There are many drugs for of symptomatic fibroids. Gonadotropin-releasing hormone (GnRH) agonists are the well known drugs. Also, aromatase inhibitors are effective. All published studies surveyed the effect of one of these two drugs. In this study as the first study decided to evaluate the effectiveness of the combination of GnRH agonists + aromatise inhibitor on the uterine fibroids. Methods: A cross-sectional prospective case series study was performed on 10 known cases of uterine fibroids late perimenopause, at least 3 myomas >5 cm, abnormal uterine bleeding and anemia due to fibroids, candidate for hysterectomy, no tendency to surgery. A single dose of Diphereline 11.25 mg, SR plus 2.5 mg of Letrozole daily for 4 weeks with add-back therapy + calcium carbonate were used. The second dose of Diphereline 11.25 mg, SR was used 3 months after the first injection. The patients were followed until 3 years. Results: The mean age of the study group was 49.90 ± 1.66. The mean fibroid size reduced from 15.05 ± 57.20 cm to 13.56 ± 39.39 cm (P = 0.012) and fibroid volume reduced from 72.78 ± 110.6 to 50.96 ± 64.2 (P = 0.116). There was no signification changes in the serum level of hormones at the end of six months. Eight cases were menopause at the end of the study and hypoestrogenism symptoms did not happened in none of the cases until the end of 24 months. Except in one case, there was no need to do surgery on others. Conclusions: Combination of Diphereline + Letrozole probably could prevent surgery in cases that have multiple fibroids, perimenopause, anemic and candidate for surgery. (J Menopausal Med 2018;24:62-66)
참고문헌 (14)
- Parker WH, "Berek & Novak's gynecology", pp.438~469 (2015), Lippincott Williams & Wilkins
- Song H, "Aromatase inhibitors for uterine fibroids", Cochrane Database Syst Rev (2013)
- 오소라, "Uterine Lipoleiomyoma in Peri or Postmenopausal Women", 대한폐경학회지, 21(3), pp.165~170 (2015), 대한폐경학회
- 정재혁, "Expulsion of Fibroids to the Endometrial Cavity after Magnetic Resonance Imaging-guided High Intensity Focused Ultrasound Surgery (MRgFUS) Treatment of Intramural Uterine Fibroids", 대한폐경학회지, 22(3), pp.139~145 (2016), 대한폐경학회
- Koskas M, "Role of medical treatment for symptomatic leiomyoma management in premenopausal women", J Gynecol Obstet Biol Reprod (Paris), 40, pp.858~874 (2011)[DOI]
- Han M, "Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2)", Eur J Obstet Gynecol Reprod Biol, 138, pp.83~88 (2008)[DOI]
- Gocmen A, "The effects of add-back therapy with tibolone on myoma uteri", Clin Exp Obstet Gynecol, 29, pp.222~224 (2002)
- Gurates B, "Treatment of symptomatic uterine leiomyoma with letrozole", Reprod Biomed Online, 17, pp.569~574 (2008)[DOI]
- Duhan N, "Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women", Eur J Obstet Gynecol Reprod Biol, 171, pp.329~332 (2013)[DOI]
- Parsanezhad ME, "A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status", Fertil Steril, 93, pp.192~198 (2010)[DOI]
- Koskas M, "Medical treatment of symptomatic uterine leiomyomata in premenopausal woman", Presse Med, 42, pp.1122~1126 (2013)[DOI]
- Ferrero S, "Letrozole monotherapy in the treatment of uterine myomas", Fertil Steril, 93, pp.e31~ (2010)[DOI]
- Biri A, "Intravenous leiomyomatosis treated with aromatase inhibitor therapy", Int J Gynaecol Obstet, 101, pp.299~300 (2008)[DOI]
- 윤건, "Benign Metastasizing Leiomyoma with Multiple Lymph Node Metastasis: A Case Report", Cancer Research and Treatment, 43(2), pp.131~133 (2011), 대한암학회